SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB AND VEDOLIZUMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE RESULTS IN HIGHER TROUGH LEVELS, AND REDUCES DAY HOSPITAL VISITS AND MEDICAL EXPENSES

Jenniina Harno-Tasihin  1     Laura Siregar  1     Mikko Paajanen  1     Perttu Arkkila  2     Jari Punkkinen  2    
1 Hyvinkää Hospital, Hyvinkää, Finland
2 Helsinki University Hospital, Helsinki, Finland

Topic
IBD

Session
The switch game: Optimal treatment modalities in IBD

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)

Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing